Tango Therapeutics Stock Net Income
TNGX Stock | USD 3.10 0.16 5.44% |
Tango Therapeutics fundamentals help investors to digest information that contributes to Tango Therapeutics' financial success or failures. It also enables traders to predict the movement of Tango Stock. The fundamental analysis module provides a way to measure Tango Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tango Therapeutics stock.
Last Reported | Projected for Next Year | ||
Net Loss | -97.4 M | -92.5 M | |
Net Loss | -101.7 M | -106.8 M | |
Net Loss | -100 M | -105 M | |
Net Loss | (1.08) | (1.13) | |
Net Income Per E B T | 1.00 | 0.80 |
Tango | Net Income |
Tango Therapeutics Company Net Income Analysis
Tango Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Tango Therapeutics Net Income | (101.74 M) |
Most of Tango Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tango Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tango Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tango Therapeutics is extremely important. It helps to project a fair market value of Tango Stock properly, considering its historical fundamentals such as Net Income. Since Tango Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tango Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tango Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Tango Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tango Therapeutics reported net income of (101.74 Million). This is 129.81% lower than that of the Biotechnology sector and 245.25% lower than that of the Health Care industry. The net income for all United States stocks is 117.82% higher than that of the company.
Tango Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tango Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tango Therapeutics could also be used in its relative valuation, which is a method of valuing Tango Therapeutics by comparing valuation metrics of similar companies.Tango Therapeutics is currently under evaluation in net income category among its peers.
Tango Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tango Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tango Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Tango Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Tango Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tango Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tango Therapeutics' value.Shares | Balyasny Asset Management Llc | 2024-09-30 | 2.7 M | State Street Corp | 2024-09-30 | 2.3 M | Adage Capital Partners Gp Llc | 2024-09-30 | 2.3 M | Deerfield Management Co | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Casdin Capital, Llc | 2024-09-30 | 1.2 M | Baker Bros Advisors Lp | 2024-09-30 | 750 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 708.4 K | Bessemer Group Inc | 2024-09-30 | 708.4 K | Trv Gp Iv, Llc | 2024-09-30 | 16.9 M | Ecor1 Capital, Llc | 2024-09-30 | 13.3 M |
Tango Fundamentals
Return On Equity | -0.49 | ||||
Return On Asset | -0.22 | ||||
Profit Margin | (2.84) % | ||||
Operating Margin | (2.83) % | ||||
Current Valuation | 77.34 M | ||||
Shares Outstanding | 107.42 M | ||||
Shares Owned By Insiders | 12.84 % | ||||
Shares Owned By Institutions | 87.16 % | ||||
Number Of Shares Shorted | 7.22 M | ||||
Price To Book | 1.45 X | ||||
Price To Sales | 7.68 X | ||||
Revenue | 36.53 M | ||||
Gross Profit | (81.05 M) | ||||
EBITDA | (111.76 M) | ||||
Net Income | (101.74 M) | ||||
Cash And Equivalents | 416.36 M | ||||
Cash Per Share | 4.73 X | ||||
Total Debt | 38.92 M | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 9.76 X | ||||
Book Value Per Share | 2.13 X | ||||
Cash Flow From Operations | (117.98 M) | ||||
Short Ratio | 2.31 X | ||||
Earnings Per Share | (1.15) X | ||||
Target Price | 11.5 | ||||
Number Of Employees | 140 | ||||
Beta | 0.88 | ||||
Market Capitalization | 333 M | ||||
Total Asset | 402.57 M | ||||
Retained Earnings | (371.26 M) | ||||
Working Capital | 300.6 M | ||||
Net Asset | 402.57 M |
About Tango Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tango Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tango Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tango Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.